 | | Vol. 24.27 – 14 August, 2023 |
| |
|
|
| The authors found that the programmed death-1 (PD-1)-triggering-receptor-expressed on myeloid cells 2 (TREM2)-targeting single-chain variable fragment (scFv) inhibited the activation of the PD-1/PD-L1 pathway.
[Molecular Cancer] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists described CAR T cells targeting tumor-associated glycoprotein-72, utilizing the CD28 transmembrane domain upstream of the 4-1BB co-stimulatory domain as a driver of potent anti-tumor activity and interferon gamma secretion.
[Nature Communications] |
|
|
|
| Investigators reported that the complementarity-determining regions loops could cause CAR clustering, leading to antigen-independent tonic signaling and subsequent CAR-T cell dysfunction.
[Nature Communications] |
|
|
|
| Researchers showed cardiac organoids engineered with electrically conductive silicon nanowires significantly enhanced the therapeutic efficacy of hPSC-derived cardiomyocytes to treat infarcted hearts.
[Science Advances] |
|
|
|
| Scientists developed a microfluidic chip that incorporated 1×, 10×, or 256× lipid nanoparticle (LNP)-generating units that achieved scalable production rates of up to 17 L/h of precisely defined LNPs.
[Proceedings Of The National Academy Of Sciences Of The United States Of America] |
|
|
|
| The authors investigated both polymeric and lipid nanoparticle formulations for eGFP-mRNA delivery to natural killer cells.
[Journal of Controlled Release] |
|
|
|
| Investigators designed and evaluated the HAUL TCR-T cell therapy based on HLA-peptide loaded membrance fusogenic deliver system.
[Bioengineering & Translational Medicine] |
|
|
|
| The authors showed that single systemic wild-type hematopoietic stem and progenitor cell transplantation rescued the Alzheimer’s disease phenotype in 5xFAD mice and that transplantation may prevent microglia activation.
[Cell Reports] |
|
|
|
| A humanized B7-H3-CAR-T was constructed, and it was evaluated that B7-H3-CAR-T cytotoxicity against solid tumor models with preconditioning of radiotherapy in vitro and in vivo.
[Life Sciences] |
|
|
|
|
| The authors evaluate the current preclinical state of liver bioengineering, the clinical context for liver cell therapies, the cell sources, the delivery routes, and the results of clinical trials for end-stage liver disease.
[Stem Cell Reports] |
|
|
|
|
| The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the US FDA has granted accelerated approval of TALVEY™.
[Johnson & Johnson] |
|
|
|
| Researchers at City of Hope were awarded $32.3 million from the California Institute for Regenerative Medicine to support three novel Phase I clinical trials evaluating innovative cell and gene therapy treatments for patients with HIV, acute myeloid leukemia, and severe aplastic anemia.
[City of Hope] |
|
|
|
|
| September 22 – 24, 2023
Ribeirao Preto, Brazil |
|
|
|
|
|
| | Creative Biolabs – New York, New York, United States |
|
|
|
| | City of Hope – Duarte, California, United States |
|
|
|
| | Harvard Medical School – Boston, Massachusetts, United States |
|
|
|
| | Center for Excellence in Molecular Cell Science – Shanghai, China |
|
|
|
| | Harvard Medical School-Brigham and Women’s Hospital – Boston, Massachusetts, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
